Emory Executes First Robotic PAE and Y-90 Mapping with LIBERTY System
Emory Healthcare performed the first robotic prostate artery embolization and Y-90 radioembolization mapping using Microbot Medical’s FDA-cleared single-use LIBERTY Endovascular Robotic System. The system demonstrated precise vascular navigation across benign prostatic hyperplasia and liver cancer cases following its limited market release in November 2025.
1. Emory Healthcare Completes First Robotic Endovascular Procedures
Emory Healthcare interventional radiologists performed the first robotic prostate artery embolization (PAE) to treat benign prostatic hyperplasia and the first robotic Y-90 radioembolization mapping for liver cancer using the LIBERTY Endovascular Robotic System.
2. Breakthrough PAE and Y-90 Applications
The robotic PAE employs fine motor control for precise catheter navigation in BPH cases affecting roughly 40 million U.S. men, while the Y-90 mapping enables personalized liver cancer treatment by delivering yttrium-90 beads directly into tumor-feeding vessels.
3. FDA Clearance and Market Rollout
The LIBERTY System holds FDA clearance as the only single-use, remotely operated robotic solution for peripheral endovascular procedures, launched in a limited market release in November 2025 with a full release planned for April 2026.
4. Growth Outlook for Microbot Medical
Widespread adoption at a leading health system is expected to validate the system's efficiency gains, potentially driving deeper market penetration and supporting revenue growth for Microbot Medical as endovascular robotics becomes standard care.